Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.58 |
| ▸ | APOBEC3A | P31941 | 3/20 | 0.57 |
| ▸ | APOBEC3G | Q9HC16 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | PRCP | P42785 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038755 | 0.98 | HDAC4 (0.62) | AKR1C1HDAC4CHRM3APOBEC3AAPOBEC3G | |
| SCHEMBL1042494 | 0.98 | HDAC4 (0.62) | AKR1C1HDAC4CHRM3APOBEC3AAPOBEC3G | |
| SCHEMBL1042365 | 0.98 | HDAC4 (0.62) | AKR1C1HDAC4CHRM3APOBEC3AAPOBEC3G | |
| SCHEMBL2481767 | 0.96 | AKR1C1 (0.58) | AKR1C1HDAC4CHRM3APOBEC3AAPOBEC3G | |
| SCHEMBL349195 | 0.92 | MEN1 (0.56) | AKR1C1HDAC4CHRM3APOBEC3AAPOBEC3G | |
| Iodomethane SCHEMBL3898463 | 0.89 | MEN1 (0.53) | AKR1C1HDAC4CHRM3APOBEC3AAPOBEC3G | |
| SCHEMBL21761835 | 0.86 | MEN1 (0.54) | AKR1C1HDAC4CHRM3APOBEC3AAPOBEC3G | |
| SCHEMBL329509 | 0.85 | AKR1C1 (0.68) | AKR1C1HDAC4CHRM3APOBEC3AAPOBEC3G | |
| SCHEMBL10105374 | 0.85 | OPRM1 (0.64) | CHRM3MEN1KMT2AHSD11B1MAPK1 | |
| SCHEMBL378799 | 0.84 | OPRM1 (0.70) | CHRM3MEN1KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117210834-A | Electrochemical-based promotion of CO 2 Method for synthesizing dicarboxylic acid compound | 四川大学 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023083343-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-10777850-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-09-15 | — | — | US | disclosed |
| CN-107078352-B | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2020-04-28 | — | — | CN | disclosed |
| US-10424812-B2 | Non-aqueous electrolytic solution and non-aqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-09-24 | — | — | US | disclosed |
| US-20190051941-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-02-14 | — | — | US | disclosed |
| US-10177414-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3203569-B1 | NONAQUEOUS ELECTROLYTE, AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY USING SAME | MITSUBISHI CHEM CORP (JP) | 2018-10-31 | — | — | EP | disclosed |
| EP-3098893-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING SAME | MITSUBISHI CHEM CORP (JP) | 2017-11-29 | — | — | EP | disclosed |
| US-20170275277-A1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2017-09-28 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-12-29 | — | — | US | disclosed |
| EP-1482935-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | Warner-Lambert Company LLC (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003074050-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-1999015524-A1 | THIAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-04-01 | — | — | WO | disclosed |
| US-5331010-A | TREATING MAMMALS FOR CONVULSIONS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1994-07-19 | — | — | US | disclosed |
| US-4684396-A | Triazole and imidazole compounds useful as plant growth regulators and fungicides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-08-04 | — | — | US | disclosed |
| EP-0153797-A1 | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275277-A1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | AKR1C1 1861/4885HDAC4 1961/4885CHRM3 3/4885 |
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | PGF, HPGDS, PTGIS | AKR1C1 2194/4885HDAC4 2088/4885CHRM3 3075/4885 |
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | AKR1C1 1431/4885HDAC4 358/4885CHRM3 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.